BB&T Investment Services Inc. Has $702,000 Stake in Regeneron Pharmaceuticals, Inc. (REGN)

BB&T Investment Services Inc. grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 48.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,556 shares of the biopharmaceutical company’s stock after purchasing an additional 505 shares during the period. BB&T Investment Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $702,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of REGN. Fieldpoint Private Securities LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $130,000. Sterling Investment Advisors Ltd. grew its position in Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 28 shares during the period. FNY Partners Fund LP grew its position in Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 200 shares during the period. IFP Advisors Inc grew its position in Regeneron Pharmaceuticals by 33.2% in the second quarter. IFP Advisors Inc now owns 385 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 96 shares during the period. Finally, Virtu KCG Holdings LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter worth approximately $206,000. Institutional investors and hedge funds own 66.67% of the company’s stock.

REGN has been the subject of several analyst reports. Canaccord Genuity set a $522.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 14th. Citigroup reiterated a “buy” rating and issued a $575.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Thursday, September 7th. Credit Suisse Group reiterated a “buy” rating and issued a $485.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. UBS lowered their price objective on Regeneron Pharmaceuticals from $535.00 to $500.00 and set a “buy” rating for the company in a research report on Thursday, September 21st. Finally, Guggenheim reiterated a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $467.84.

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $378.37 on Tuesday. The company has a market capitalization of $40,125.25, a price-to-earnings ratio of 32.33, a price-to-earnings-growth ratio of 1.47 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. Regeneron Pharmaceuticals, Inc. has a 52 week low of $340.09 and a 52 week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period last year, the firm earned $3.13 earnings per share. sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 13.55 EPS for the current fiscal year.

In other news, SVP Robert E. Landry sold 663 shares of the stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $498.60, for a total value of $330,571.80. Following the sale, the senior vice president now directly owns 10,099 shares in the company, valued at $5,035,361.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the stock in a transaction on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the completion of the sale, the director now owns 11,000 shares in the company, valued at $4,950,000. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,163 shares of company stock worth $1,943,072. Insiders own 10.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BB&T Investment Services Inc. Has $702,000 Stake in Regeneron Pharmaceuticals, Inc. (REGN)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/05/bbt-investment-services-inc-has-702000-stake-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply